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Abstract
Stroke is the world’s second leading cause of mortality, with a high incidence of severe morbidity in surviving
victims. There are currently relatively few treatment options available to minimize tissue death following a stroke.
As such, there is a pressing need to explore, at a molecular, cellular, tissue, and whole body level, the mechanisms
leading to damage and death of CNS tissue following an ischemic brain event. This review explores the etiology
and pathogenesis of ischemic stroke, and provides a general model of such. The pathophysiology of cerebral
ischemic injury is explained, and experimental animal models of global and focal ischemic stroke, and in vitro
cellular stroke models, are described in detail along with experimental strategies to analyze the injuries. In
particular, the technical aspects of these stroke models are assessed and critically evaluated, along with detailed
descriptions of the current best-practice murine models of ischemic stroke. Finally, we review preclinical studies
using different strategies in experimental models, followed by an evaluation of results of recent, and failed
attempts of neuroprotection in human clinical trials. We also explore new and emerging approaches for the
prevention and treatment of stroke. In this regard, we note that single-target drug therapies for stroke therapy,
have thus far universally failed in clinical trials. The need to investigate new targets for stroke treatments, which
have pleiotropic therapeutic effects in the brain, is explored as an alternate strategy, and some such possible
targets are elaborated. Developing therapeutic treatments for ischemic stroke is an intrinsically difficult endeavour.
The heterogeneity of the causes, the anatomical complexity of the brain, and the practicalities of the victim
receiving both timely and effective treatment, conspire against developing effective drug therapies. This should in
no way be a disincentive to research, but instead, a clarion call to intensify efforts to ameliorate suffering and
death from this common health catastrophe. This review aims to summarize both the present experimental and
clinical state-of-the art, and to guide future research directions.
Introduction
Stroke is the world’s second leading cause of mortality,
resulting around 6,000,000 deaths annually [1]. It is esti-
mated that the lifetime risk for stroke is between 8%
and 10% [2]. Pathogenically, stroke involves a heteroge-
neous group of processes. Vessel occlusions (ischemic
stroke) account for 85% of all strokes, while primary
intracerebral bleeding (hemorrhagic stroke) accounts for
the remainder [3]. Embolisms cause approximately 75%
of all cerebral vessel occlusions, and are the most fre-
quent cause of focally-obstructed blood flow within the
brain [4]. Ischemia is defined as a reduction in blood
flow sufficient to alter normal cellular function. Brain
tissue is exquisitely sensitive to ischemia, such that even
brief ischemic periods to neurons can initiate a complex
sequence of events that ultimately may culminate in cel-
lular death. Different brain regions have varying thresh-
olds for ischemic cell damage, with white matter being
more resilient than gray matter [5]. In addition, certain
populations of neurons are selectively more vulnerable
to ischemia; for example, in the hippocampus, CA1 pyr-
amidal neurons are highly susceptible to ischemia,
whereas dentate granule neurons are more resistant [5].
Early restoration of blood flow remains the treatment
of choice for limiting brain injury following stroke.
Improved educational efforts that emphasize recognition
of the early signs and symptoms of stroke, coupled with
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patients with acute ischemic stroke, has decreased mor-
bidity and mortality following stroke [6,7]. While reperfu-
sion of the ischemic brain is clearly desirable, tissue
damage often results from both the transient ischemic
insult and the reperfusion process; the latter process
inducing an inflammatory response that causes additional
injury to the cerebral microcirculation and adjacent brain
tissue [8]. Hence, a rapidly evolving area of emphasis in
stroke research involves defining the molecular and cellu-
lar basis for the augmented tissue injury and inflamma-
tion associated with transient cerebral ischemia. Clinical
evidence suggests that the majority of stroke patients
exhibit a slow evolution of brain injury that occurs over a
period of hours-to-days following the attack. This win-
dow of opportunity, limited though it is, is sufficient to
provide a clinically practical target period for therapeutic
intervention, with the ultimate goal of inhibiting the pro-
gression of tissue damage that normally results from
both ischemia and reperfusion [9]. There are two major
categories of experimental brain ischemia; namely, global
and focal ischemia. In global-ischemia models, typically,
two or four cervical vessels are temporarily interrupted
and circulation restored after some delay [10,11]. In
focal-ischemia models, the middle cerebral artery is typi-
cally occluded, either permanently or temporarily, to
allow reperfusion [12,13]. We performed a comprehen-
sive search of the scientific literature on the pathophy-
siology of ischemic stroke, experimental in vivo and in
vitro stroke models, drug development and preclinical
studies and clinical trials in ischemic stroke. A literature
search for relevant articles was conducted using Pubmed,
Web of Science, NIH Stroke Trials Registry and Google
Scholar search. Articles were included if they met the fol-
lowing inclusionary criteria: (a) written in English, (b)
published in a peer-reviewed journal, (c) primarily
focused on ischemic stroke, and (d) primarily used quan-
titative research methods.
This review considers the etiology and pathogenesis of
ischemic stroke, and provides a model for each facet.
The pathophysiology of cerebral ischemic injury is ela-
borated, and experimental animal models of global and
focal ischemic stroke, as well as in vitro stroke models,
are illustrated in detail, with the different experimental
strategies to analyze the injuries, explained. Finally, we
analyse previous preclinical studies that used differing
strategies in experimental models, as well as the results
of human neuroprotection and revascularization trials,
and, finally, emerging approaches for the prevention and
treatment of stroke.
Ischemic Stroke Pathophysiology
The pathophysiology of stroke is complex and involves
numerous processes, including: energy failure, loss of
cell ion homeostasis, acidosis, increased intracellular cal-
cium levels, excitotoxicity, free radical-mediated toxicity,
generation of arachidonic acid products, cytokine-
mediated cytotoxicity, complement activation, disruption
of the blood-brain barrier (BBB), activation of glial cells,
and infiltration of leukocytes (Figure 1). These are inter-
related and co-ordinated events, which can lead to
ischemic necrosis, which occurs in the severely affected
ischemic-core regions. Within a few minutes of a cere-
bral ischemia, the core of brain tissue exposed to the
most dramatic blood flow reduction, is mortally injured,
and subsequently undergoes necrotic cell death. This
necrotic core is surrounded by a zone of less severely
affected tissue which is rendered functionally silent by
reduced blood flow but remains metabolically active
[14,15]. Necrosis is morphologically characterized by
initial cellular and organelle swelling, subsequent disrup-
tion of nuclear, organelle, and plasma membranes, disin-
tegration of nuclear structure and cytoplasmic organelles
with extrusion of cell contents into the extracellular
space [14,15]. The region bordering the infarct core,
Figure 1 Major cellular patho-physiological mechanisms of
ischemic stroke. Ischemia-induced energy failure leads to the
depolarization of neurons. Activation of specific glutamate receptors
dramatically increases intracellular Ca
2+, and Na
+, and K
+ is released
into the extracellular space. Edema results from water shifts to the
intracellular space. Increased levels of intracellular messenger Ca
2+
activates proteases, lipases and endonucleases. Free radicals are
generated which damage membranes, mitochondria and DNA, in
turn triggering cell death and inducing the formation of
inflammatory mediators, which then induce JNK, p-38, NFB and
AP-1 activation in glial cells, endothelial cells, and infiltrating
leukocytes. This culminates in pro-inflammatory cytokine and
chemokine secretion and leads to the invasion of leukocytes via up-
regulation of endothelial adhesion molecules.
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half of the total lesion volume during the initial stages
of ischemia, and represents the region in which there is
opportunity for salvage via post-stroke therapy [16].
Less severe ischemia, as occurs in the penumbra region
of a focal ischemic infarct, evolves more slowly, and
depends on the activation of specific genes and may
ultimately result in apoptosis [17-19]. Recent research
has revealed that many neurons in the ischemic penum-
bra, or peri-infarct zone, may undergo apoptosis only
after several hours or days, and thus they are potentially
recoverable for some time after the onset of stroke. In
contrast to necrosis, apoptosis appears to be a relatively
orderly process of energy-dependent programmed cell
death to dispose of redundant cells. Cells undergoing
apoptosis are dismantled from within in an organized
way that minimizes damage and disruption to neighbor-
ing cells [15]. There are two general pathways for activa-
tion of apoptosis: the intrinsic and extrinsic pathways.
Over the last decade, experimental studies have pro-
vided considerable new information characterizing apop-
totic processes occurring after ischemic stroke.
Glutamate excitotoxicity
A significant portion of ischemia-induced neuronal
damage is mediated by excessive accumulation of excita-
tory amino acids, leading to toxic increases in intracellu-
lar calcium [20]. Although thisi sa ni n t r i n s i cd e f e n s i v e
response to protect against ischemia by activating a
reaction to severe cell stress, paradoxically, this increase
in intracellular calcium activates multiple signaling path-
ways, which ultimately leads to cell death. Soon after
reduction or termination of cerebral blood flow, energy-
dependent cellular pumps fail due to a fall in glucose-
dependent ATP generation, resulting in the flow
of numerous ionic species into the cell. This results in
cellular swelling through osmosis and cellular depolari-
zation. Calcium ions (Ca
2+)e n t e rt h ec e l lt h r o u g hv o l -
tage-dependent and ligand-gated ion channels, resulting
in activation of a number of proteases, kinases, lipases,
and endonucleases, triggering of the intrinsic apoptotic
pathway and thus ending in cell death by [18,21]. Gluta-
mate, which is the major excitatory neurotransmitter in
the brain, accumulates in the extracellular space follow-
ing ischemia, and activates its receptors [22]. Glutamate
receptor activation induces alterations in the concentra-
tion of intracellular ions, most notably Ca
2+ and sodium
ions (Na
+) (Figure 1). Elevations of intracellular Na
+ can
be detrimental to neuronal survival at earlier time points
after ischemia [23]. However, experimental studies
groups suggest that glutamate toxicity is primarily
dependent on Ca
2+ influx [24,25]. Collectively, these
results suggest that cellular self-harm processes exist
within the brain itself, but also, that stroke-induced cen-
tral nervous system (CNS) damage may be reduced by
medicinal strategies to relieve the tendency of the brain
to injure itself, under conditions of stroke. The inflam-
matory paradox of cellular self-injury is amplified by the
special sensitivity of CNS neurons to sudden deprivation
of oxygen and glucose; the catastrophic temporal and
anatomical nature of stroke conspires with these realities
to produce consequences that are difficult to treat with
medicines, and thus far, this has been a challenge
beyond the capacities of modern medicine.
Oxidative stress
Increasing evidence suggests that oxidative stress and
apoptosis are closely linked phenomena in the patho-
physiology of ischemic stroke. Neurons are normally
exposed to a baseline level of oxidative stress from both
exogenous and endogenous sources, as are all cells in
the body. Free radicals are highly reactive molecules
with one or more unpaired electrons. Free radicals can
react with DNA, proteins, and lipids, causing varying
degrees of damage and dysfunction [26,27]. Numerous
experimental and clinical observations have shown
increased free radical formation during all forms of
stroke injury [26,28]. Free radicals, involved in stroke-
induced brain injury, include superoxide anion radical,
hydroxyl radical and nitric oxide (NO). The damaging
effects of free radicals are normally prevented or
reduced by antioxidant enzymes and free radical scaven-
gers [29,30]. The primary source of oxygen-derived free
radicals (often referred to as ‘reactive oxygen species’)
during ischemic-stroke injury is the mitochondria,
which produce superoxide anion radicals during the
electron transport process [28]. Another potentially
important source of superoxide in post-ischemic neu-
rons, is the metabolism of arachidonic acid through the
cyclooxygenase and lipooxygenase pathways [31,32].
Oxygen free radicals can also be generated by activated
microglia and infiltrating peripheral leukocytes via the
NADPH oxidase system following reperfusion of
ischemic tissue [33]. This oxidation causes further tissue
damage, and is thought to be an important trigger mole-
cule for apoptosis after ischemic stroke.
NO is generated from L-arginine through one of sev-
eral NO synthase (NOS) isoforms. The neuronal form
(nNOS), which requires calcium/calmodulin for activa-
tion, is expressed by subpopulations of neurons
throughout the brain [34]. Inducible NOS (iNOS) is
expressed by inflammatory cells such as microglia and
monocytes. These two isoforms are, for the most part,
damaging to the brain under ischemic conditions. A
third isoform found in endothelial cells (eNOS), has
vasodilatory effects and is likely to play a beneficial role
by improving local blood flow [35]. NMDA receptor
activation has been shown to stimulate nitric oxide
(NO) production by nNOS, and to possibly play a role
in excitotoxic-mediated injury in ischemic stroke [36].
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superoxide at it point of generation to produce peroxy-
nitrite (ONOO
-), another highly reactive oxygen species
[29]. Both oxygen-derived free radicals and reactive
nitrogen species are involved in activating several path-
ways involved in cell death following stroke, such as
apoptosis and inflammation [37-39]. A reduction of oxy-
gen supply also leads to the accumulation of lactate via
anaerobic glycolysis and so to acidosis [40-43].
Lipid peroxidation
Besides the production of different species of oxygen
radicals, acidosis also interferes with intracellular protein
synthesis. Lipid peroxidation appears to play a promi-
nent role in the pathogenesis of stroke. The mechanism,
whereby membrane lipid peroxidation induces neuronal
apoptosis, involves generation of an aldehyde called 4-
hydroxynonenal (4-HNE), which covalently modifies
membrane transporters such as the Na
+/K
+ ATPase,
glucose transporters and glutamate transporters, thereby
impairing their function [44]. Whilst potentially dama-
ging via their direct actions, Ca
2+ and free radicals can
also activate neuroprotective transcription factors,
including nuclear factor-B( N F - B), hypoxia-inducible
factor 1 and interferon regulatory factor 1 [17]. Some of
these transcription factors induce the expression of
inflammatory cytokines (for example, IL-1, IL-6 and
TNF-a) and chemokines (for example, IL-8 and MCP-
1), endothelial cell adhesion molecules (for example,
selectins, ICAM-1 and VCAM-1), and other proinflam-
matory genes (for example, interferon-inducible protein-
10) [17,45].
Inflammation
There are several resident cell populations within brain
tissue that are able to secrete proinflammatory media-
tors after an ischemic insult. These include endothelial
cells, astrocytes, microglia and neurons. Activation of
transcription factors results in increased protein levels
for cytokines and increased expression of endothelial
cell adhesion molecules (CAMs) in post-stroke brain tis-
sue [46-48]. A major role in brain inflammation follow-
ing stroke is attributed to microglia, especially in the
penumbral region of damage [49]. Activated microglia
produce numerous proinflammatory cytokines, as well
as toxic metabolites and enzymes [47,50]. In addition to
microglial cells, astrocytes also have an important part
in stroke-induced brain inflammation. These cells can
produce both proinflammatory cytokines and neuropro-
tective factors, such as erythropoietin, TGFb1, and
metallothionein-2 [4]. Because of the mixed nature of
microglial and astrocyte products (both destructive and
protective factors), the overall role of glia may differ at
different time points following stroke insult, with pro-
tective or regenerative activities occurring days to weeks
after the onset of ischemia [49,51]. These factors add
layers of complexity, in both adducing their pathophy-
siological roles in stroke, and in the goal of developing
new therapeutics for stroke therapy.
Blood Brain Barrier (BBB) dysfunction
The brain endothelium is quite distinctive compared
with other organs, as evidenced by the blood brain bar-
rier (BBB). However, it responds to stroke injury with
increased permeability and diminished barrier function,
along with degradation of the basal lamina of the vessel
wall, as occurs as in other organs after ischemic injury
[52]. Similarly, there is considerable evidence that acute
ischemic stroke enhances the interactions of brain
endothelium with extravascular CNS cells (astrocytes,
microglia, neurons), as well as intravascular cells (plate-
lets, leukocytes), and that these interactions contribute
to the injury process [45]. The net result of all these
responses to stroke is that the cerebral vasculature
assumes the following phenotypes: 1) poor capillary per-
fusion of brain tissue, 2) pro-adhesive for circulating
cells, 3) pro-inflammatory, 4) pro-thrombogenic, and 5)
diminished endothelial barrier function. These changes
in normal physiological functions cumulate with each of
these inflammatory responses tilting in the same detri-
mental direction, such that the end-result is harmful to
the host CNS cells and tissues. Indeed, this is the central
problem facing rapid and effective treatment of stroke.
Leukocyte infiltration
There is a large body of evidence that implicates leuko-
cytes in the pathogenesis of stroke injury. The conten-
tion that leukocytes mediate reperfusion-induced tissue
injury and microvascular dysfunction is supported by
three major lines of evidence: 1) leukocytes accumulate
in post-ischemic tissues prior to the onset of tissue
injury, 2) animals rendered neutropenic exhibit a dimin-
ished injury response to ischemic stroke, and 3) preven-
tion of leukocyte-endothelial cell adhesion with
monoclonal antibodies (mAbs) directed against specific
leukocyte or endothelial CAMs also affords substantial
protection against stroke injury [45]. Polymorphonuclear
leukocytes, of which neutrophils predominate, are there-
fore heavily implicated in worsening stroke outcome.
Neutrophils adhere to endothelial ischemic brain vascu-
lature in the acute phase following stroke, and infiltrate
into brain parenchyma [53-56]. Rodents, with reduced
circulating neutrophils (through the use of antineutro-
phil serum), show reduced infarct volumes and
improved neurological outcomes, also indicating a
pathogenic role of neutrophil accumulation and activa-
tion following stroke [57,58]. In contrast, the pathophy-
siological significance of lymphocyte recruitment into
the brain after ischemic stroke remains uncertain. How-
ever, recent studies have shown important roles for
T-lymphocytes in mediating reperfusion injury in post-
ischemic brain tissue [8,59]. How lymphocytes and
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unknown.
Novel injury mechanisms
Recent experimental studies have shown several novel
mechanisms to also play a role in ischemic stroke-
induced brain injury. Our groups have shown that a
novel CNS-specific protein, Pancortin-2, interacts with
the actin-modulating protein, Wiskott-Aldrich syndrome
protein verprolin homologous-1 (WAVE1), and Bcl-xL,
to form a mitochondrial-associated protein complex,
that attenuates neuronal apoptosis during focal cerebral
ischemia in adult, but not embryonic, cerebral cortical
neurons [60].
We have also shown that CNS neurons expressed sev-
eral Toll Like Receptors (TLRs), and that TLR-activated
pro-apoptotic signaling cascade involving jun N-terminal
kinase (JNK) and the transcription factor AP-1 occurs
during ischemic stroke, and is TLR 2- and 4-mediated
[61,62]. Other such novel receptor-mediated signaling
mechanisms are activated during ischemic stroke, also
include Notch and Adiponectin receptors [63-65]. We
have recently shown that gamma secretase, and adipo-
nectin-mediated signaling, through their respective cell-
surface receptors; NOTCH-1 and ADR-1 (adiponectin
receptor-1), exacerbated neuronal apoptosis during focal
ischemic stroke, and in combined oxygen- and glucose-
deprived neurons respectively [63,64].
Collectively, these results demonstrate that there are
multiple pathways influencing stroke outcome, and that
there are correspondingly multiple pathways yet to be
explored as new potential therapeutic targets for stroke
therapy. The below sections will proffer recent advances
in the development of animal models of stroke: in parti-
cular, the technical aspects of current stroke models will
be assessed, and the state-of-the-art, as such, critically
evaluated, along with a detailed description of the meth-
odology of the current best-practice murine models of
ischemic stroke.
Animal Models of Ischemic Stroke
Animal models have been developed that closely resem-
ble stroke injury seen in human patients. Many experi-
mental models are used to study this injury, and
mechanisms of cell damage are determined by testing
effects of different manipulations on the extent of cell
stress or death in any particular model. The three main
classes of in vivo animal stroke models are 1) global
ischemia, 2) focal ischemia, and 3) hypoxia/ischemia.
The last-mentioned method, in which vessel occlusion is
combined with breathing a hypoxic gaseous mixture, is
almost exclusively used in young animals [66,67].
Global ischemic insults are most commonly produced
by multiple vessel occlusion, and less commonly by
complete brain circulatory arrest. In focal ischemic
stroke models, the middle cerebral artery (MCA) is the
most commonly occluded vessel; the vessel can be
occluded either permanently or transiently, and damage
results from both ischemia and reperfusion. Collateral
blood flow may play a role in reducing the initial impact
of the occlusion. Intracerebral hemorrhage frequently
accompanies ischemic stroke, mainly because of disrup-
tions of the BBB [68-70]. The choice of species for
studying stroke in animals is usually limited to labora-
tory species, such as rodents. There are many advan-
tages to using small animals such as rats and mice in
stroke models. These species are relatively inexpensive
and their cranial circulatory anatomy is similar to
humans [71]. It is also possible to control the severity,
duration and location of the vessel occlusion. Physiologi-
cal factors can be well-controlled and histopathology
allows for assessment of ischemic pathogenesis and tis-
sue infarction.
Global ischemic stroke model
It has been claimed that the focal stroke models are of
greater relevance than other models to the typical
human stroke situation. However, global ischemia of the
brain is of clear clinical relevance to cardiac arrest and
asphyxia in humans [12]. In addition, it should be noted
that the physiological, biochemical and functional mea-
surements made during recovery from a global model of
reversible ischemia may be important in identifying the
molecular and cellular mechanisms and pharmacological
actions of potential neuroprotective agents. Global mod-
els of cerebral ischemia may thus be as useful as broader
focal models, provided that care is taken in the interpre-
tation of the data. The three most widely used animals
in models of global ischemia are: 1) rat - four-vessel
occlusion (4-VO) or two-vessel occlusion (2-VO) com-
bined with hypotension; 2) gerbil - 2-VO; and 3) mouse
- 2-VO. A 2-VO mouse model was developed for stu-
dies in transgenic mice and is now being routinely uti-
lised [12,68,72].
Rat models of global stroke
Four-vessel occlusion (4-VO) This model has several
advantages, including ease of preparation, a high inci-
dence of predictable ischemic neuronal damage, a low
incidence of seizures, and the absence of anesthesia (i.e.,
at the time of carotid occlusion) [73]. This particular
model has been, and still is, widely used to investigate
the effectiveness of potential therapeutic agents [12].
The rat 4-VO model involves permanent coagulation of
the vertebral arteries, which alone has no deleterious
effects, and temporary ligation of the two common caro-
tid arteries. Experimental results show loss of righting
reflex within 15 s, and a blood flow decrease to only 3%
of control values in hippocampus, striatum, and neocor-
tex [12,74].
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under a general anesthetic and requires the administra-
tion of a muscle relaxant. It has been well-documented
that a bilateral occlusion of the common carotid arteries
alone is insufficient either to bring the cerebral blood
flow down below the ischemic threshold, or to upset the
energy state of the brain tissue to an extent sufficient to
produce detectable cell death [10,75]. To produce a
damaging ischemic insult, the brain blood flow has to
be further reduced using hypotension at the same time
as the carotid arteries are occluded. The hypotension is
normally produced in one of three ways: 1) controlled
exsanguination, 2) adjunct administration of peripheral
vasodilators, or 3) a combination of both approaches.
The ligation of both common carotid arteries along with
a blood pressure reduction to 50 mm Hg causes as
much, or more, damage than 4-VO. Blood flow falls to
~3-5% in the hippocampus, neocortex, and striatum.
However, in some cases blood flow is reduced to ~15%
of control levels [12,76].
Gerbil model of global ischemic stroke
This is induced by temporarily ligating the carotid
arteries, with no reduction in blood pressure. Because
there are no posterior communicating arteries in gerbils,
this produces profound forebrain ischemia. The changes
in regional CNS blood flow are similar to those in the
rat models; blood flow in the cortex is ~1%, and in the
hippocampus ~4% of control values [77].
Mouse models of global ischemic stroke
Mouse models of global stroke are similar to rat 2-VO
models using bilateral occlusion of the common carotid
arteries. Several studies have demonstrated mouse global
ischemia models with quantitatively uniform injury to
hippocampal CA1 neurons, using techniques including
2-VO and 2-VO with hypotension [78]. However,
because of the variability of collateral flow via the pos-
terior communicating artery, it has been difficult to
obtain uniform injury in the CA1 region, whilst still
retaining high survival and experimental success rates.
One model combines basilar artery occlusion with bilat-
eral common carotid artery occlusion (three-vessel
occlusion; [79]). However, in this model the animal sur-
vival rate is low, and CA1 neuronal injury is inconsis-
tent. Because the mouse basilar artery runs through a
narrow groove in the brain stem, and is attached to the
pia mater and arachnoid membrane with arachnoid tra-
beculae, it is technically difficult to isolate and occlude.
Complete global ischemia
Complete global ischemia is generally achieved by neck-
cuff, cardiac arrest, or by ligating or compressing all
arteries from the heart [80]. Blood flow to the whole
brain is zero or <1% in these models. Due to a very high
mortality associated with this model, it is not widely
used.
Focal ischemic stroke models
Focal ischemic stroke models, whether in larger mam-
mals such as cats, dogs or non-human primates, or in
rodents, usually involve occlusion of one MCA
[18,81-83]. Focal ischemia is differentiated from global
ischemia in two ways. First, even at the core of the
lesion, the blood flow is almost always higher than dur-
ing global ischemia, so that longer insults are required
to cause damage than for global ischemia. Secondly,
there is a significant gradation of ischemia from the
core of the lesion to its outermost boundary, and hence
there are different metabolic conditions within the
affected site. Because of its duration and heterogeneity,
the insult is much more complex than in global ische-
mia, but it is an invaluable and realistic model for
human stroke, and is thus widely studied.
There are two models of focal ischemic stroke, 1)
transient focal ischemia and 2) permanent focal ische-
mia. In transient focal ischemia models, vessels are
blocked for periods of up to 3 hours, followed by pro-
longed reperfusion; whereas, in permanent focal ische-
mia, the arterial blockage is maintained throughout an
experiment, usually for one or more days.
Transient middle cerebral artery (MCA) occlusion
There are two principal occlusion sites in this model
(Figure 2). In proximal occlusion, the MCA is occluded
close to its branching from the internal carotid artery,
before the origin of the lenticulostriate arteries. A
newer, and now widely used approach to proximal
Figure 2 Surgical technique for inducing global or focal
cerebral ischemia in mouse. Schematic illustration of arteries
demonstrating the three points of occlusion (black arrows) for
global ischemia (3-VO) and red arrows for focal ischemia. MCA:
middle cerebral artery; ICA: internal carotid artery; ECA: external
carotid artery; BA: basilar artery; CCA: common carotid artery.
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the carotid artery, past the point at which the MCA
branches, so that the latter is occluded at its origin.
The procedure is as follows: After a midline neck inci-
sion, the left external carotid artery (ECA) and pterigo-
paratine artery are isolated and ligated with silk thread.
The internal carotid artery (ICA) is occluded at the per-
ipheral site of the bifurcation of the ICA, and the pteri-
goparatine artery, with a small clip and the common
carotid artery (CCA) is ligated with silk thread. The
ECA is cut and a nylon monofilament, whose tip is
blunted (0.20-0.22 mm for mouse) with a coagulator, is
inserted into the ECA. The ECA and the inserted nylon
thread are tightened with a silk suture, which prevents
bleeding during advancement of the nylon thread and
during its removal at the time of reperfusion, and
rotated for its advancement into the ICA. After removal
of the clip at the ICA, the nylon thread is advanced
until light resistance is felt; the distance from the nylon
thread tip to the ICA-pterygopalatine artery bifurcation
is slightly more than 6 mm (mouse) and the distance to
the ICA-ECA bifurcation is slightly less than 12 mm.
During MCA occlusion, the parietal bone becomes pale
on the occluded side and laser Doppler flowmetry
reveals that blood flow in this area falls to less than 20%
of baseline [84]. The nylon thread and the CCA ligature
are removed after an occlusion period and reperfusion
occurs with release of blood flow from ICA.
There are some potentially important artifacts with
this widely-used method. Blood flow following tempor-
ary ischemia is somewhat compromised by the partial
occlusion of the carotid arteries with the filament and
there is quite extensive damage to small arteries in the
ischemic field, including damage to endothelial and
smooth muscle cells. It has been suggested that this
damage may affect subsequent neuronal cell death, by
exacerbating the leukocyte response in the reperfusion
period [8,45,85].
Permanent middle cerebral artery (MCA) occlusion
The commonly-used permanent focal ischemia model
involves occlusion of one or more branches of the
MCA. The MCA is exposed via a trans-temporal
approach. After the temporalis muscle is retracted, a 2-3
mm burr hole is drilled 2-3 mm rostral to the fusion of
the zygomatic and squamosal bones. The MCA is
exposed after opening and retracting the dura mater.
Using a steel hook maneuvered via a micromanipulator,
the MCA is elevated and electrocoagulated [86,87].
Another commonly-used permanent focal ischemia
model involves occlusion of the MCA using a thread
and leaving the thread in place up to 24 h [88].
Embolic model of focal ischemia The procedure for
this model is similar to the transient focal ischemic
model [89]. Briefly, a longitudinal incision is made in
the midline of the ventral cervical skin. The CCA, ICA
and ECA are exposed. The distal portion of the ECA is
ligated with two sutures and the ECA is cut between
these two sutures. A silk suture is tied loosely around
the origin of the ECA. The CCA and ICA are tempora-
rily clamped using microvascular clips. A small puncture
is made on the wall of the ECA with a pair of spring
scissors. A modified PE-10 catheter connected with a
PE-50 tubing (40 mm in length for 10 ml thrombus and
20 mm for 5 ml), filled with bovine thrombin is intro-
duced into the lumen of the ECA via the puncture. The
suture around the origin of the ECA is tightened and
the clip on the ICA is removed. After the blood is with-
drawn, the catheter is advanced up in the ICA until its
tip is 1-2 mm away from the origin of the MCA. The
catheter is retained there for 15 min to allow formation
of a clot. Once the clot has formed, it is then gently
injected into the MCA. The catheter in the ICA is
removed 5 min after the clot injection and the ECA is
ligated.
Photothrombotic distal middle cerebral artery (MCA)
occlusion The use of a photochemical reaction to pro-
duce focal cortical ischemia in the rat brain was first
described in 1985 [90]. In this model, vascular thrombo-
sis is induced by transcranial illumination with a filtered
light source in combination with intravenous injection
of a photosensitive dye [91,92]. Electron microscopy and
light microscopy studies showed intravascular thrombo-
tic material, red blood cell stasis, and platelet aggregates
adhering to luminal surfaces inside blood vessels, with
intravascular thrombosis that is responsible for the
occurrence of ischemia leading to infarction. Increased
permeability through disruption of the BBB by the
photochemical reaction is also involved in this type of
model. The method involves mounting the rat in a
stereotaxic head-holder, and making a 1-1.5 cm vertical
incision between the right eye and ear. With the aid of
an operating microscope, a burr hole is made with a
high-speed drill. Care should be taken not to injure the
dura mater. The distal segment of the right MCA is
thus exposed. A krypton laser operating at 568 nm
(Innova 301, Coherent Inc, or 643-Y-A01, Melles Griot
Inc) is used to irradiate the distal MCA at a power of
20 mW for 4 minutes. The laser beam is focused with a
30 cm focal length convex lens and positioned with a
mirror onto the distal MCA. The photosensitizing dye,
normally rose bengal or erythrosin B (15-25 mg/mL in
0.9% saline), is administered intravenously at a dose of
20 mg/kg over 90 seconds, starting simultaneously with
4 min of laser irradiation.
In vitro models to study ischemic stroke injury
Brain slices, particularly the hippocampal slice, and pri-
mary neuronal/glial cultures from cortex, hippocampus
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have become widely used models for studying ischemia-
like damage. Ischemia-like conditions are induced by
replacing the normal O2/CO2 equilibrated medium with
N2/CO2 equilibrated medium; typically the cultures are
maintained in an incubator containing a N2/CO2 atmo-
sphere. When glucose is maintained in the anoxic buf-
fer, the insult is termed hypoxia, and when glucose is
omitted, the insult is termed in vitro ischemia or oxy-
gen/glucose deprivation (OGD). Glucose deprivation
(GD) alone can also induce neuronal death with some
features similar to those observed in the in vivo ische-
mia models [93,94]. Hypoxia can also be induced by
treatment with cyanide (NaCN or KCN) or by incubat-
ing in an anoxic atmosphere. Chemical hypoxia results
in more free radical generation than does anoxia [63].
In vitro models differ from in vivo stroke models in sev-
eral aspects. Typically, a rather longer duration of the
anoxic or hypoxic insult is required to kill neurons
in vitro. ATP depletion is less severe and the release of
glutamate is delayed compared to ischemia in vivo.T h e
absence of blood vessels and blood flow in vitro elimi-
nates important structural and functional components
of the damage process present in vivo,i n c l u d i n gt h e
infiltration of inflammatory cells. In addition, the com-
position and responsiveness of glial cells in vitro differs
from that in the intact brain [50,95,96].
Despite these obvious differences between the two
experimental systems, there are surprisingly pleasing
similarities in the way isolated cells behave under condi-
tions of substrate stress, and the way the same cells
behave under the catastrophic conditions of stroke,
in vivo [84]. Thus, we have a simple, highly controlled
experimental system providing detailed basic informa-
tion as to how that cell type responds to oxygen and
glucose deprivation; on the other hand, the reality of the
complexity of the architecture of the brain also demands
a model of ischemic stroke in vivo. That these two
approaches complement one another so well is an unu-
sual feature in animal models of disease, and this happy
congruence can only benefit research in this area.
Organotypic brain slice culture
Another in vitro approach of studying neurons in the
CNS are organotypic brain slice culture techniques.
These have many advantages as the neuronal morphol-
ogy, cellular and anatomical relations and network con-
nections are maintained in these types of cultures
[97-99]. Organotypic slice cultures of the brain have
been used increasingly to examine neuronal cell death,
mechanisms of cell migration, myelination, electrophy-
siological activities and synapse plasticity. They have
also been used to investigate basic cellular mechanisms
and treatment strategies for ischemic stroke [100-103].
The principle of this approach is based on ex vivo
cultures derived from different anatomical regions of the
CNS [104], and the donor sources most commonly used
are rats and mice.
Most organotypic brain slice cultures are obtained
from neonatal (P0-P10) animals. The two main culturing
methods for slice cultures include: the roller drum tech-
nique introduced by Gähwiler [105], and the interface
cultures developed by Stoppini [106]. Slices maintained
in stationary culture with the interface method are ide-
ally suited for three-dimensional structure studies,
whereas those cultured in roller tubes are often
employed for imaging experiments. In OGD studies
using these cultures, the cell death and apoptotic
changes in neurons can be studied by looking at cellular
uptake of propidium iodide and Fluro-jade staining,
TUNEL staining and immunofluorescent staining for
cleaved caspase-3, respectively. With growing demands
for working experimental models that can replace or
reduce animal experiments, such cultures certainly seem
to offer a lot of promise in studying ischemic stroke
in vitro.
Primary Neuronal Culture
Timed pregnant female mice or rats at days fifteen to
seventeen of gestation (E15-17) are normally used as a
source of embryos for primary cortical neuronal collec-
tion [107]. The pregnant mice are anaesthetized and
fetuses are collectively removed. The mouse fetuses are
decapitated and the heads separated and collected into
ice-cold HEPES-buffered (10 mM) Hanks balanced sal-
ine solution (HBBS) lacking Ca
2+ and Mg
2+. The brains
are then removed and placed in HBSS in petri dishes,
where the meninges and blood vessels are stripped off
the surface. Under sterile conditions, the cerebral hemi-
spheres are dissected from the brains with the aid of a
dissecting microscope and a trans-illumination light
source. The isolated cerebral tissues are then pooled
into another petri dish containing HBSS and minced
into smaller pieces for enzymatic dissociation. The tis-
sues are then transferred to sterile 15 ml tubes contain-
ing 3-5 ml of HBSS containing 0.2% trypsin. Following a
15-20 min incubation in the trypsin solution, the tissue
pieces are rinsed with fresh HBSS and incubated for
5 min in 0.1% soybean trypsin inhibitor to halt the pro-
tease reaction. Following another wash in HBBS, cells
are further dissociated by triturating the tissue, using a
narrowed bore sterile pasteur pipette, until most of the
visible-sized tissue pieces have been disrupted. Aliquots
of cell suspension are added to growth substrate-coated
cell culture dishes containing Neurobasal medium with
B-27 supplement (Invitrogen, USA). The culture plate-
coating substrates that are known to work well for pri-
mary neuronal culture are poly-L-lysine, poly-D-lysine
and polyethylene imine (PEI) [107,108]. The choice of
substrate depends on the nature of experiment [107].
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perature, the dishes are washed 2-3 times with phos-
phate buffered saline (PBS) and allowed to dry. The
dishes are sterilized by exposure to UV light for 10 min
and culture medium is added to the dishes. Cells are
allowed to attach to the substrate-coated dishes for 3-6
hours and maintained in a humidified incubator (37°C
with air and 6% CO2). The cell culture medium is then
replaced with fresh medium a few hours later. Generally
the neurons are allowed to mature over 5-7 days before
experimentation.
Primary Glial Culture
Astrocytes account for about 50% of the cell population
in adult mammalian brains. In addition to providing
structural, metabolic and trophic support to neurons,
their role in protecting neurons from injurious stimuli is
slowly being unraveled [109-111]. Consequently, study-
ing them under in vitro conditions is cardinal to under-
standing their role in stroke pathology. Astrocyte cell
cultures are normally obtained from one to three day
postnatal (P1-P3) mouse/rat pups. The heads are
removed from pups and placed in a Petri dish with ice-
cold HBSS containing 2% sucrose. The meninges are
then stripped off and the mice cerebra are dissected
aseptically from the residual parts of the brain. The
cerebra are then cut carefully into small pieces. The tis-
sue pieces are trypsinised following a 10 min incubation
with 0.25% trypsin. Trypsin inactivation is achieved by
adding Dulbecco’s Modified Eagle Medium (DMEM)
containing 10% fetal bovine serum and an antibiotics
mix of penicillin (100 IU/ml), streptomycin (100 mg/ml)
and amphotericin (0.25 mg/ml). The cerebra are disso-
ciated by passing them through a fire-polished Pasteur
pipette and the resultant cell suspension is allowed to
settle for about 5 min, to allow for decantation of the
large, uncleaved cell clusters. The supernatant is then
c e n t r i f u g e df o ra b o u t5m i na t1 5 0 0 - 2 0 0 0r p ma tr o o m
temperature. The cell pellet is then dispersed in the new
volume of the medium and plated on either T-75 or T-
25 culture flasks at a density of about 5 million cells/ml.
Following the initial seeding of cells, the medium is
replaced once every 3 days. The resulting culture
obtained is a mixed culture of astrocytes, microglia and
oligodendrocytes. Microglia are microscopically visible
on days 6-7 of the culture, remaining suspended in
media as well as adhered to the bed layer of astrocytes.
The remaining microglia and oligodendrocytes are sepa-
rated from the bed layer of astrocytes by shaking the
culture flasks on a rotary shaker placed in the incubator
for at least 10 hours [112] and the media from this flask
is then harvested to obtain pure microglial cultures. The
remaining undetached cells are relatively pure astro-
cytes, and are detached following trypsin incubation for
about 10 min. After addition of an equal amount of the
new growth medium, the cells are centrifuged and the
cell pellet is re-dispersed by gentle pipetting and seeded
onto new culture flasks. Following a 3 hour incubation,
this medium is aspirated out and new volume (about
10 mL) of growth medium is added. This applied proce-
dure allows for a high purity of astrocytes to be obtained
with routine culturing [113].
Glucose deprivation (GD) or oxygen/glucose deprivation
(OGD) experiments
For GD, cultured neurons are incubated in glucose-free
Locke’s medium, pH 7.2, supplemented with gentamycin
(5 mg/L) for 6, 12 or 24 hours. In order to mimic in
vitro, transient focal ischemic strokes that occur in vivo,
the neuronal cultures are exposed to OGD. The original
glucose-containing neurobasal medium is replaced with
ag l u c o s e - f r e eL o c k e ’s buffer containing no serum. All
m e d i ac h a n g e sa r ef o l l o w e db yw a s h e sw i t hs t e r i l eP B S
(pH 7.4). Following this, the cultures dishes are exposed
to hypoxia (PO2 <50 mm Hg) by placing them in a
small, 3 L, airtight experimental hypoxia chamber (Bill-
ups-Rothenberg, San Diego, CA) with inflow and out-
flow connectors and circulating a hypoxic gas mixture
of 95% N2/5% CO2 mixture for 15-20 min [84]. Cultures
are exposed to conditions of OGD for 1, 3, 6, 12 or
24 hrs.
Measurement of ischemic stroke damage in animal
models
The measurement of dynamic changes in the ischemic
brain has attracted growing attention. Ischemic brain
injury in both focal and global ischemia models evolves
as a progressive sequence of cellular and molecular
events [17]. In this section we describe methods for ana-
lyzing brain injury and dynamic changes in the brain
during ischemia and reperfusion.
Cerebral blood flow analysis and physiological variables
Regional microvascular tissue perfusion (cerebral blood
flow) is normally monitored before, during, and after
focal ischemia, using laser Doppler flowmetry. The
values during ischemia are calculated as a percentage of
the pre-occlusion level. The region of measurement is
set at 1 mm rostral and 1 mm dorsal to the cross-over
point of the left MCA and rhinal fissure, which is in the
ischemic penumbra of the ischemic lesion [114]. Blood
pressure, rectal temperature, and blood gases are mea-
sured during the operation in rats and mice. Normally,
under controlled conditions using heating pads, there
are no significant differences in temperature or blood
pressure monitored at pre-, intra-, and post-ischemic
time points in most studies. However, measuring and
maintaining these parameters is important for proper
interpretation of the technical procedure causing stroke,
outcomes among animals, as well as for evaluating
adhering leukocytes, which is accomplished by intravital
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venules is obtained by fluorescence microscopy based
on image analysis determinations of the maximal velo-
city of fluorescently-labeled red blood cells or platelets
within the venules under study [116,117]. Such esti-
mates of pseudo-shear rate in venules are obtained
using measurements of venular diameter (Dv) and the
maximal velocity of flowing platelets (Vplt) according to
the formula: pseudo-shear rate = (Vplt/1.6)/Dv × 8
[116].
Quantification of cerebral infarction
The size of the brain infarct in focal cerebral ischemia
increases during the period of reperfusion (Figure 3).
This has been shown in animal models of stroke and in
human stroke patients [118]. The infarct volume is nor-
mally analyzed after 12-24 hours in transient and per-
manent focal ischemia models. The brain is removed
and coronal sections are cut (2 mm-thick slices in rats
or 1-2 mm thick slices in mice) through the entire ros-
tro-caudal extent of the cerebral cortex. The slices are
immersed in a 2% solution of 2,3,5-triphenyltetrazolium
chloride (TTC). An edema index is calculated by divid-
ing the total volume of the hemisphere ipsilateral to the
MCA occlusion by the total volume of the contralateral
hemisphere. An infarction index, the actual infarcted
lesion size adjusted for edema, is then calculated for
each animal [119].
Neurological assessment
The functional consequences of focal ischemic stroke
injury are evaluated using a 5-point scale neurological
deficit score (0, no deficit; 1, failure to extend right paw;
2, circling to the right; 3, falling to the right; and 4,
unable to walk spontaneously) [120]. More recently a 14
point neurological scoring system was developed [121].
This new scoring method includes the results of motor,
reflex and balance tests; a single point is awarded for
the inability to perform the test or for the lack of a
tested reflex.
Blood-brain barrier function
Albumin leakage, a quantitative index of endothelial bar-
rier dysfunction, can be applied to the brain for determi-
nation of BBB integrity. Albumin extravasation in the
brain can be quantified either by fluorescence imaging
of the leakage of fluorescein isothiocyanate-labeled albu-
min, or sulforhodamine (Texas Red)-labelled albumin
from cerebral venules, or from the clearance of the
same fluorochromes from blood to the artificial CSF
perfusing the brain surface [122,123]. With this imaging
approach, fluorescently tagged albumin is administered
intravenously to the animals 15 minutes before the base-
line observation period and fluorescence intensity is
detected using a silicon-intensified target camera. The
fluorescence intensities within a specified segment of
cerebral venules within the cranial window and in a
contiguous area of perivenular interstitium are measured
at various times after administration of fluorescent-albu-
min using a computer assisted digital imaging processor
(NIH Image 1.61 on a Macintosh computer). Vascular
albumin leakage is determined from the difference in
fluorescence intensity between the outside and inside of
the venular segment.
Brain edema measurement
The brains are immediately removed and divided into
contralateral and ipsilateral hemispheres. The tissue
samples are weighed on an electronic analytical balance
to the nearest 0.1 mg to obtain the wet weight. The tis-
sue is then dried at 90-100°C for 24 hours to determine
the dry weight. Brain water content (%) is calculated as
{(wet weight-dry weight)/wet weight} × 100.
Assessment of leukocyte and platelet adhesion
Adhesion of leukocytes and platelets following ischemia
and reperfusion can be monitored in vivo using intravi-
tal video microscopy (Figure 4). The head of the animal
is immobilized and a hole drilled through the skull
using a high-speed micro drill (1 mm posterior from
bregma and 4 mm lateral from the midline). The dura
mater is not cut because the fluorescently labeled blood
cells are easily observed and intracranial pressure is
well-maintained with the dura mater intact. Artificial
cerebrospinal fluid is placed on the exposed brain tissue.
For focal ischemia models, the observation area includes
the infarcted region following MCA occlusion [124]. For
global ischemia models, the observation area includes
the entire cerebral cortex. Platelets are isolated from a
donor animal using a series of centrifugation steps and
labeled ex vivo with carboxyfluorescein diacetate succini-
midyl ester. Once the platelet data are collected, endo-
genous leukocytes are labeled in vivo by infusing
Figure 3 Representative coronal brain section from a mouse
that had been subjected to MCA occlusion-reperfusion. This
mouse had a one hour MCA occlusion and 72 hours reperfusion.
The red staining indicates healthy brain tissue and the white
indicates damaged tissue.
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to circulate an additional 5 min before observation. An
upright Nikon microscope equipped with a SIT camera
(C2400-08; Hamamatsu Photonics) and a mercury lamp
is used to observe the cerebral microcirculation. The
images are received by a CCD video camera and
recorded on a video recorder equipped with a time-date
generator (WJ-810; Panasonic).
Quantification of cell activation and adhesion molecule
expression
The dual radiolabelled monoclonal antibody (mAb) tech-
nique is used to quantify the expression of different
endothelial cell adhesion molecules, including P-selectin,
ICAM-1 and VCAM-1, in the microvasculature of the
brain. This method determines the relative accumulation,
in any regional vascular bed, of a binding mAb to a
specific endothelial surface epitope (eg, P-selectin) and
an isotype-matched non-binding mAb, the latter of
which is used to compensate for non-specific accumula-
tion of the binding mAb. Different endothelial cellular
adhesion molecules in the brain can be analyzed follow-
ing ischemic stroke. However, adhesion molecules speci-
fically expressed by immune cells such as LFA-1 are
analyzed at least 24 hours after reperfusion. Activation of
microglial cells following ischemia or reperfusion is nor-
mally analyzed using CD11b (Mac-1/CR3) antibodies.
Magnetic resonance imaging (MRI)
With different MRI techniques, in vivo diagnostic and
prognostic information can be obtained on edema for-
mation, hemodynamics, tissue structure, neuronal acti-
vation, cell migration, gene expression and more. In
addition, MRI can be combined with other imaging
modalities such as positron emission tomography or
optical imaging to obtain complementary or supplemen-
tary information. Advances in magnetic resonance tech-
nology, such as magnets with higher field strength,
more powerful gradient systems and increasing availabil-
ity of targeted magnetic resonance contrast agents, allow
MRI research in animal models of ischemic and hemor-
rhagic stroke with higher sensitivity, faster acquisition,
and improved specificity (see [125] for review).
Measurement of protein and mRNA levels in the ischemic
brain
Identification and quantification of specific proteins and
mRNAs in situ and in brain tissue samples can provide
valuable information to elucidate the signaling pathways
and molecular mechanisms involved in ischemic brain
damage and recovery from stroke. Proteins can be iden-
tified en masse by proteomic methods and individual
proteins can be quantified by immunoblot or enzyme-
linked immunosorbent assays [126,127]. Specific
mRNAs are detected and quantified by polymerase
chain reaction (PCR)-based gene array methods and by
real-time PCR (see [128] for review).
Measurement of damage in in vitro ischemic stroke
models
Trypan blue exclusion test of cell viability
This test is based on the principle that live cells possess
intact cell membranes that exclude certain dyes, such as
trypan blue, whereas dead cells do not possess this abil-
ity. Hence, following OGD/GD conditions the dead cells
would have altered membrane permeability, thereby
facilitating the entry of this dye into the cell and stain-
ing the cytoplasm blue, and the live cells would have a
clear cytoplasm (Figure 5). This test is performed by
adding trypan blue into control normoxic neuronal
plates containing NB medium or OGD/GD- exposed
neuron plates containing glucose deprived-Locke’sB u f -
fer. Following 3-5 min incubation with trypan blue, the
Sham
I/R 12 h
I/R 24 h
Figure 4 Representative images of leukocyte interactions in
pial microcirculation of a sham-operated mouse and in mice
which underwent 1-hour MCA occlusion and 12 or 24-hour
reperfusion. Sham-operated animals show minimal leukocyte
adhesion. Scale bar 50 μm.
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maldehyde and counted under a normal light micro-
scope. In each field, the dead and total number of cells
is counted and their ratio provides an estimate of per-
centage cell death [129].
MTT-assay
Cell viability can also be assessed colorimetrically using
the 3-(4, 5-dimethylthiazol-2-yl)-2,5 -diphenyl tetrazo-
lium bromide (MTT) assay [130,131]. MTT is added to
the cultures and incubated at 37°C for 40 min. Follow-
ing this incubation, the media is aspirated and DMSO is
used to solubilise the blue formazan product. The cell
plates are then assessed using a spectrophotometer at
5 7 0n ma n dt h el i v ec e l lp e r c e n t a g ec a nb ec o m p a r e d
between control normoxic and OGD-exposed cell plates.
Fluorescent analysis of necrosis and apoptosis
Cells undergoing apoptosis or necrosis following OGD
conditions in vitro can be visualised using fluorescent
stains like propidium podide (PI) and Hoechst 33258.
Similar to trypan blue, PI is taken up only by dead cells.
Hoechst 33258, on the other hand, is a nuclear stain
and stains all nuclei of both viable and dead cells. This
method is carried out by adding PI (10 μM) to the neu-
ronal cultures 6-12 hours after OGD. The cells are then
f i x e di ni c e - c o l d4 %b u f f e r e df o r m a l d e h y d e .H o e c h s t
staining is carried out post-fixation by incubating the
cultures with Hoechst 33258 (1 μg/mL) for 10 min at
room temperature. The cells are then analyzed under a
nonconfocal fluorescent microscope. The results are
interpreted as follows: the nuclei of viable cells are blue-
intact Hoechst positive and PI-negative, the nuclei of
apoptotic cells are red- PI-positive and fragmented (or
condensed), and the nuclei of necrotic cells are red- PI-
positive and round [132]. Both the apoptotic and necro-
tic cells also stain blue Hoechst-positive.
Current therapeutics and preclinical studies
The fundamental question in translating results of ani-
mal experiments to clinical use is whether or not the
pathophysiologic processes in animal models are rele-
vant to those in human disease. Queries may arise
regarding differences in anatomy and physiology, the
pathophysiological response to injury, or between injury
mechanisms in animal models and those in human dis-
ease. All of these issues are relevant and pertinent.
Therapeutic manipulations generally work best when
administered before, or immediately after the insult.
Experiments with animal models often begin with a pre-
treatment protocol, to sensibly determine the proof-of-
principle of the agent in the model under study. If the
therapy works, it is then tested at different intervals
from injury onset, to mimic clinical realities. In animal
models of human stroke, most effective therapies work
best within 15-30 minutes of the stroke insult; rarely are
they effective after more than 3 hours from onset of
injury. The most important step in limiting ischemia is
the quick restoration of blood flow that occurs either
naturally, or with the aid of thrombolytic drugs. Yet,
this also contains the seeds of further destruction to tis-
sues in the CNS; the reperfusion injury following an
ischemic insult magnifies the clinical challenges of treat-
ing stroke. Hence, the concern is not merely related to
shortening the timing of therapy after the initial insult,
but also the knowledge that there are other pathological
mechanisms lurking, which are often more dangerous
than the precipitating events causing the stroke.
Intravenous recombinant tissue plasminogen activator
(rtPA) is the first-, and only-, approved agent for the
treatment of acute stroke [133]. Tissue plasminogen
activator (tPA) is a serine protease that catalyzes the
activation of the zymogen plasminogen by converting it
to the broad-specificity, active protease, plasmin. In
Normal
OGD 12 h
Figure 5 Representative images of neuronal cell death
following 12 h oxygen and glucose deprivation (OGD). Dead
cells have altered membrane permeability, thereby facilitating the
entry of trypan blue (yellow arrow) into the cell and staining the
cytoplasm blue, whereas the live cells have a clear cytoplasm.
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NINDS trial using rtPA showed a highly significant
improvement in outcome in treated patients. However,
based on later examination of the outcomes of rtPA-
treated patients, the benefit of rtPA was not as robust as
originally predicted [134]. It has been reported that tPA
can exacerbate excitotoxic neuronal death [135], sug-
gesting an adverse effect of this drug that may, in part,
counteract its clot-dissolving action.
Another treatment that shows promise is hypothermia,
which may decrease metabolic demand and extend neu-
ron survival [136,137]. Additional therapeutic
approaches target the processes involved in calcium
overload, glutamate excitotoxicity, oxygen radical pro-
duction, apoptosis and inflammation.
Calcium-stabilizing agents
Cell death cascades in ischemic stroke are mediated, in
part, by excessive calcium influx resulting from activa-
tion of glutamate receptors and voltage-dependent cal-
cium channels (VDCC). In addition, the function of
Ca
2+-ATPases is compromised, resulting in prolonged
elevation of the intracellular calcium concentration.
Drugs that block glutamate receptors (eg, MK-801) or
VDCC (eg, nimodipine and flunarazine) have proven
effective in rodent models of stroke [138]. At least 14
clinical trials of nimodipine in ischemic stroke were
conducted beginning in the mid 1980s. Nine trials
found no effect, one trial found short-term worsened
outcome with treatment, and four trials found positive
outcomes [139]. Clinical trials with flunarizine found no
statistically significant improvement in outcome [140].
Despite this discouraging analysis, dantrolene, which
blocks ryanodine receptors, has been discussed for clini-
cal trials as the result of beneficial effects in rodent
stroke models [141].
Anti-excitotoxic agents
Several compounds that interfere with glutamate receptor
activation have been developed and tested against experi-
mental animal models of stroke as well as against human
clinical trials. The noncompetitive NMDA antagonist MK-
801 (dizocilpine) improved outcome in models of focal
ischemia producing up to 75% reductions in infarct
volume [142,143]. Both MK-801 and dextromorphan,
another noncompetitive NMDA receptor antagonist,
exhibited protective effects in experimental studies, but
clinical trials were terminated early because of phencycli-
dine-like psychotic side effects and lack of efficacy against
stroke injury [144]. Some other noncompetitive (aptiganel,
ceresine,) or competitive (selfotel, eliprodil) NMDA recep-
tor antagonists were shown to be very effective in animal
stroke models, but with no significant effects in clinical
trials [139]. Non-NMDA antagonists have also been devel-
oped and studied against stroke conditions. Zonampanel
(YM-872) is an AMPA antagonist tested in human Phase
2 clinical trials [145]. In addition, another AMPA antago-
nist, SPD-502, as well as metabotropic glutamate receptor
modulators, are being developed and tested against stroke
injury in animals and humans [9,139]. However, the devel-
opment of anti-excitotoxic agents against stroke has thus
far been disappointing.
Antioxidants
Free radical production is enhanced in both the ischemic
core and penumbra following stroke injury, and this is
believed to cause much of the damage seen in these
regions. There are many agents that either block free radi-
cal production or inhibit its activation that have been
shown to be very effective in experimental models. Uric
acid is a well-known natural antioxidant present in fluids
and tissues. Administration of uric acid resulted in a
large and significant reduction in ischemic damage and
improved behavioral outcome [146]. Edaravone, tetra-
methylpyrazine, alpha-phenyl-N-tert-butyl-nitrone,
FR210575 and NXY-59 are some of other free radical inhi-
bitors that have been shown to be effective against experi-
mental stroke injury [147,148]. Completed clinical trials
with free radical scavengers, however, have had limited
success after acute ischemic stroke. The free-radical-trap-
ping agent, NXY-59, was initially reported to be efficacious
in acute ischemic stroke [149], however a follow-up trial in
a larger cohort of patients failed to demonstrate efficacy
[150]. EGb-761 (Tanakan
®), being developed by Ipsen, is a
free radical scavenger derived from a concentrated extract
of Ginkgo [151], that has recently completed a Phase
3 clinical trial with results still pending [152].
Anti-apoptotic agents
Accumulating evidence strongly suggests that apoptosis
contributes to neuronal cell death in stroke injury. Cas-
pases, a family of cysteine-aspartate proteases that
include at least 14 members divided into three groups
(I, II, and III), are essential players in apoptotic neuronal
cell death [153]. Many groups have studied the effects
of caspase inhibition on cerebral ischemia-induced neu-
rodegeneration by using the broad spectrum caspase
inhibitor z-VAD, either in the fluoromethylketone (fmk)
or dichlorobenzoyloxopentanoic acid (dcb) form and
z-DVED-fmk. Both inhibitors were neuroprotective in
mouse models of transient cerebral ischemia and z-VAD
was neuroprotective also in transient and permanent
models in the rat [154]. Ac-YVAD-cmk (Ac-Tyr-Val-
Ala-Asp-cmk), a caspase group I (caspase-1-like) inhibi-
tor, also was shown to be neuroprotective in a mouse
transient model of cerebral ischemia [154]. In addition,
peptide-based caspase inhibitors have been shown to
prevent neuronal loss in animal models of stroke [155].
To date however, the efficacy of anti-apoptotic agents in
human stroke patients has not yet been tested.
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Inflammation in stroke is characterized by the accumu-
lation of leukocytes and activation of resident microglial
cells. Inflammatory cells can contribute to stroke pathol-
ogy through two basic mechanisms. They form aggre-
gates in the venules after reperfusion, or, enter infarcted
tissue and exacerbate cell death through production of
free radicals and cytokines [8,53]. Cell adhesion mole-
cules such as selectins, integrins, and ICAMs permit
endothelial-inflammatory cell interactions. Treatment
with anti-selectin antibodies successfully decreased
infarct volume by up to 70% after transient focal ische-
m i ai nm i c e[ 1 5 6 ] .A na n t i - I C A M - 1a n t i b o d yh a sa l s o
been shown to decrease infarct size after transient, but
not permanent, focal ischemia [157]. However, a recent
clinical trial using the murine anti-ICAM-1 antibody
enlimomab, worsened neurologic score and mortality in
patients and a follow-up study using the murine anti-rat
ICAM-1 antibody in rats also found an increase in
infarct volume and no efficacy [158,159]. It is believed
that immune activation in response to the foreign
mouse protein probably accounted for the failed clinical
and follow-up experimental results [159]. Recently, a
Phase 2 trial using anti-CD11b/CD18 agent UK-279276,
has been completed, and demonstrated that this com-
pound is safe and well-tolerated [160]. Other targets
include the mitogen activated protein kinases (MAPK),
which have been linked to inflammatory cytokine pro-
duction and cell death in ischemic stroke injury. SB-
239063 is a MAPK inhibitor that reduced infarct size
and improved neurological outcome following focal
stroke in rodents, which may be an alternative target to
limit inflammation in human stroke patients [161].
Matrix metalloproteinases (MMPs) are enzymes that
break down components of the extracellular matrix and
enhance BBB breakdown after stroke, promote hemor-
rhage, and increase inflammation. MMP inhibitors such
as BB-94 and KB-R7785 show decreased infarct volume
in treated mice after permanent focal ischemia [162].
MMP inhibitors have been evaluated in patients for
their anti-angiogenic properties and are well-tolerated
[163]. Although chemokines can have pro- or anti-
inflammatory actions, the overall effect of chemokine
up-regulation in ischemia-reperfusion injury is detri-
mental. NR58-3.14.3, a novel broad-spectrum inhibitor
of chemokine function significantly reduced lesion
volume in rats by up to 50%, and this was associated
with a marked functional improvement [164]. Several
other anti-inflammatory cytokine approaches were
tested in experimental stroke models, including various
a n t i b o d i e st h a tt a r g e ti n f l a mmatory proteins. However,
there have been no successful clinical trials of such anti-
inflammatory agents reported so far. As mentioned ear-
lier in this review, microglial activation following stroke
insult plays a role in promoting inflammatory processes,
but therapeutic approaches that specifically target
microglia are currently lacking.
Emerging approaches for the treatment of ischemic stroke
Brain tissue injury following ischemic stroke results
from the complex interplay of excitotoxicity, oxidative
stress, inflammation and apoptosis. As mentioned above,
two decades of basic research targeting single stroke
injury mechanisms, in single-cell types, or in single-
injury mechanisms in multiple cell types, have failed
completely when applied in clinical trials of human
strokes. On the basis of the complexity of events in cer-
ebral ischemia and the disappointing results from
human clinical stroke trials using single agent, it is
unrealistic to anticipate that a single neuroprotective
drug will demonstrate benefits in human stroke. Given
this consistent finding, we believe that a new pleiotropic
approach in stroke treatment is required, and that tar-
geting more diverse pathogenic events in multiple cell
types may prove a superior approach over the classical,
single-target one.
We have recently identified Gamma-secretase inhibi-
tors (GSIs) as a novel and potent stroke therapy [63].
Specifically, we reported that ischemic stroke can transi-
ently activate gamma-Secretase (g-secretase), and a sin-
gle treatment with GSIs reduced ischemic brain damage
and improved recovery by targeting diverse pathogenic
mechanisms in multiple cell types [63]. The concept
raised by our findings, that GSIs are potentially neuro-
protective after stroke, was broadened by another study
which showed that GSIs are beneficial for the treatment
of traumatic brain injury [165].
Intravenous immunoglobulin (IVIG) is a therapeutic
modality approved for the treatment of various condi-
tions, and is increasingly used for autoimmune disorders
to suppress immune-mediated tissue damage, particu-
larly in neuro-autoimmune diseases [166]. We have
recently shown that administration of IVIG to mice sub-
jected to experimental stroke almost entirely eliminated
mortality and reduced the size of brain infarction by 50-
60% [84]. Moreover, not only was the infarcted area
reduced, but also, within this ischemic region, neurons
were spared and only occasional cell loss was observed.
In additional studies we provided evidence that IVIG
can directly protect neurons against ischemia-like condi-
tions [84]. The efficacy of IVIG against stroke-induced
brain injury in our study was due, in part, to its ability
to selectively neutralize complement components, and
by reducing cell adhesion molecule production and sub-
sequent infiltration of inflammatory cells, and thus redu-
cing inflammation in the infarcted region [84].
In further studies, our group provided evidence that
IVIG can directly protect neurons against ischemia-like
conditions. We found that OGD in cultured neurons
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active) caspase-3 (a marker of apoptosis) and a progres-
sive decrease in neuronal viability. Treatment with IVIG
suppressed the OGD-induced increases in activated cas-
pase-3 levels, suggesting the IVIG protects against neu-
ronal cell death directly, by as yet unknown mechanisms
[84]. In light of the extensive clinical experience with
IVIG for other indications [85,166,167], our results may
support consideration of the development of clinical
trials to evaluate the use of IVIG in human stroke
patients.
Similar to IVIG and GSIs, statins may have potential
pleiotropic effects against ischemic stroke-induced brain
injury [168]. Statins reduce cholesterol levels, which
have been related to a reduction in vascular event risk,
but they also have pleiotropic effects such as regulation
of NO and glutamate metabolism, modulation of inflam-
matory repsonses, reductioni np l a t e l e ta g g r e g a t i o n ,
immune dampening activity, and anti-apoptotic effects,
as well as potentially promoting angiogenesis [169-171].
Recent clinical studies suggest a neuroprotective effect
of statins during the acute phase of stroke. It has been
found that patients under treatment with statins prior to
suffering stroke, showed higher probability of favourable
outcome at three months, compared with those without
previous treatment with statins, despite similar stroke
severity at admission [172]. This beneficial effect is also
observed in those patients who received thrombolytic
therapy with rtPA [173]. Furthermore, recent prospec-
tive data indicated that the cessation of statin medica-
tion in acute ischemic stroke patients confers a
significantly higher likelihood of early neurological dete-
rioration and poorer outcomes [168]. The promising
pleiotropic action of statins could also be extended to
the field of neurorepair after ischemic stroke.
Conclusions
Ischemic stroke-induced brain injury results from the
interaction of complex pathophysiological processes.
The molecular biology of stroke injury is a rapidly grow-
ing field of research, that may lead to the identification
of novel stroke targets and directed therapies. Mechan-
isms of CNS cell damage are determined experimentally
by testing effects of different manipulations on the
extent of cell death in animal and CNS brain cells
in vitro, and in CNS tissue slice culture models.
Several different models of stroke have been devel-
oped. The three main classes of in vivo animal models
are global ischemia, focal ischemia, and hypoxia/ische-
mia. Technological advances and experimental discov-
eries have begun to define the cellular and molecular
mechanisms involved in stroke injury. Exploration of
these targets has led to the development of numerous
agents that target various injury pathways. However,
despite clear demonstration of numerous agents that
can prevent the cascade of events leading to ischemic
neuronal death in animal models, there is no obvious
neuroprotective agent that has been shown to conclu-
sively improve stroke outcome in humans. The inconsis-
tency between animal results and clinical trials may be
due to several factors including: the heterogeneity of
human stroke, morphological and functional differences
between the brain of humans and animals, the relatively
long post-stroke delay in administration of the drugs in
clinical trials, and the better experimental control of
physiological variables such as temperature, blood pres-
sure, and differences in evaluating efficacy in animal
models.
The window of therapeutic opportunity in animal
models is not necessarily predictive of the time window
in humans, but the determination of relative windows is
useful. In animal models, the time of the stroke or
ischemic onset is known precisely, as is the administra-
tion of drug at precise times, whereas in humans this is
less often the case. There are a number of important
issues that remain unresolved regarding the translation
of experimental developments to the clinical setting.
Novel interventions will be required to overcome hur-
dles associated with bench-to-bedside translation.
We propose that a new paradigm for drug development
for stroke treatment is required. Instead of focusing on
single molecular targets on single cell types - which has
so far been a clinical failure, we suggest that targets with
more global signaling pathways and diverse cell loci, be
investigated. We call this the pleiotropic approach to
stroke treatment. New, broad-spectrum agents being cur-
rently investigated, such as IVIG and GSIs may prove
more fruitful therapeutically in this regard.
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